AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35503613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 120
Study 35503613 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 120
Study 33585959 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic RAMPS using the flip-up approach
Number of subjects: 0
Study 34261052 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated environment (HOT; ∼36 °C) during supine position (SUP)
Number of subjects: 0
Study 34261052 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated environment (HOT; ∼36 °C) during orthostatic position (ORT)
Number of subjects: 0
Study 34261052 — intervention group
Group type: COMPARATOR
Intervention: Thermal reference (TC; ∼24 °C) during supine position (SUP)
Number of subjects: 0
Study 34261052 — intervention group
Group type: COMPARATOR
Intervention: Thermal reference (TC; ∼24 °C) during orthostatic position (ORT)
Number of subjects: 0
Study 34865586 — intervention group
Group type: EXPERIMENTAL
Intervention: G100 20 µg/dose
Number of subjects: 18
Study 34865586 — intervention group
Group type: EXPERIMENTAL
Intervention: G100 plus pembrolizumab
Number of subjects: 18
Study 32662661 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical wound negative pressure drainage (Group 1)
Number of subjects: 1162
Study 32662661 — intervention group
Group type: COMPARATOR
Intervention: No surgical wound drainage (Group 2)
Number of subjects: 1162
Study 32662661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1162
Study 32303761 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 124
Study 32303761 — intervention group
Group type: COMPARATOR
Intervention: Non-OAT
Number of subjects: 124
Study 35356068 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with resistance training
Number of subjects: 111
Study 35356068 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone (Control Group)
Number of subjects: 111
Study 34088702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year lifestyle intervention
Number of subjects: 2184
Study 33222584 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3438
Study 33222584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3438
Study 35303190 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Acceptance and Commitment Therapy (ACT) intervention for hazardous drinking
Number of subjects: 23
Study 32757446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Meloxicam
Number of subjects: 0
Study 32757446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34609029 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (30 mg, two tablets of 15 mg per day for 8 weeks)
Number of subjects: 44
Study 34609029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35674760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1079
Study 35674760 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 1079
Study 33681988 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH modulation (recombinant human AMH protein supplementation during the secondary-to-early antral stage followed by neutralizing anti-human AMH antibody)
Number of subjects: 19
Study 33681988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AMH modulation)
Number of subjects: 19
Study 32716061 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (sutured apically to the periosteum)
Number of subjects: 28
Study 32716061 — intervention group
Group type: COMPARATOR
Intervention: Control group (flap margin left free)
Number of subjects: 28
Study 34053095 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet-based intervention ‘Hypos can strike twice’ provided by ambulance personnel
Number of subjects: 4825
Study 34053095 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet-based intervention ‘Hypos can strike twice’
Number of subjects: 4825
Study 35723748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bone graft substitute (CBGS)
Number of subjects: 45
Study 35723748 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft autograft
Number of subjects: 45
Study 34428334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided adductor canal block with 0.25% bupivacaine
Number of subjects: 60
Study 34428334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided adductor canal block with 0.16% bupivacaine
Number of subjects: 60
Study 34428334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adductor canal block)
Number of subjects: 60
Study 34428334 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 60
Study 36190377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac), Mycophenolate mofetil (MMF), and Prednisolone (TMP)
Number of subjects: 38
Study 36190377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac), Sirolimus (SRL), and Prednisolone (TSP)
Number of subjects: 38
Study 33774715 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total 12 (CT)
Number of subjects: 48
Study 33774715 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Kingdom (BK)
Number of subjects: 48
Study 33774715 — intervention group
Group type: EXPERIMENTAL
Intervention: Black is White (BW)
Number of subjects: 48
Study 33774715 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate optic white (COW)
Number of subjects: 48
Study 35639174 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 339
Study 33004382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restricted exercise (BFRE) for 8 weeks preoperatively
Number of subjects: 84
Study 33004382 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study 36592046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3158
Study 34076641 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal pedicle flap
Number of subjects: 40
Study 34076641 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Number of subjects: 40
Study 34076641 — intervention group
Group type: COMPARATOR
Intervention: No soft tissue grafting or plastic surgery
Number of subjects: 40
Study 32229185 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-powered positioning system with wedges
Number of subjects: 0
Study 32229185 — intervention group
Group type: COMPARATOR
Intervention: Ceiling lift with pillows
Number of subjects: 0
Study 34520250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 109
Study 34520250 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 109
Study 33207580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi with Thera-Band (TCTB) exercise
Number of subjects: 40
Study 33207580 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi exercise only
Number of subjects: 40
Study 33143432 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 50
Study 32364756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 150
Study 32364756 — intervention group
Group type: EXPERIMENTAL
Intervention: TGC perfusion chemotherapy
Number of subjects: 150
Study 32364756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib + TGC perfusion chemotherapy
Number of subjects: 150
Study 35686189 — intervention group
Group type: EXPERIMENTAL
Intervention: Online remote behavior therapy
Number of subjects: 40
Study 35686189 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face behavior therapy
Number of subjects: 40
Study 32856190 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + DHA (FA 800 μg/d + DHA 800 mg/d)
Number of subjects: 240
Study 32856190 — intervention group
Group type: EXPERIMENTAL
Intervention: FA (FA 800 μg/d)
Number of subjects: 240
Study 32856190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (DHA 800 mg/d)
Number of subjects: 240
Study 32856190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 32352391 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBT group (n=45)
Number of subjects: 70
Study 32352391 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 70
Study 36458132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% menthol gel
Number of subjects: 27
Study 36458132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% menthol gel
Number of subjects: 27
Study 36458132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% menthol gel
Number of subjects: 27
Study 36458132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% menthol gel
Number of subjects: 27
Study 36458132 — intervention group
Group type: EXPERIMENTAL
Intervention: All menthol gels
Number of subjects: 27
Study 36458132 — intervention group
Group type: COMPARATOR
Intervention: CON (non-menthol, flavor-matched placebo)
Number of subjects: 27
Study 32701392 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (CUR)
Number of subjects: 23
Study 32701392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study 34545696 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Global Assessment score (SGA)
Number of subjects: 116
Study 34545696 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Nutritional Assessment Questionnaire (SNAQ)
Number of subjects: 116
Study 34545696 — intervention group
Group type: EXPERIMENTAL
Intervention: INSYST2 score
Number of subjects: 116
Study 34545696 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Global Assessment score (SGA) in multivariate analysis
Number of subjects: 116
Study 35702815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother vignette
Number of subjects: 270
Study 35702815 — intervention group
Group type: COMPARATOR
Intervention: Foster care vignette
Number of subjects: 270
Study 35702815 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD diagnosis
Number of subjects: 270
Study 33431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-analgesics treatment
Number of subjects: 463
Study 33431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-no analgesics
Number of subjects: 463
Study 33431262 — intervention group
Group type: EXPERIMENTAL
Intervention: No pain-analgesics treatment
Number of subjects: 463
Study 33431262 — intervention group
Group type: EXPERIMENTAL
Intervention: No pain-no analgesics
Number of subjects: 463
Study 33431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity scores
Number of subjects: 463
Study 32051492 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC plus CCRT
Number of subjects: 1378
Study 32051492 — intervention group
Group type: COMPARATOR
Intervention: NAC plus IMRT alone
Number of subjects: 1378
Study 35095011 — intervention group
Group type: EXPERIMENTAL
Intervention: Trataka (Yogic visual concentration) practice
Number of subjects: 106
Study 35095011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study 34057124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsata honey (DH) given orally three times a day at a dose of 15 ml
Number of subjects: 30
Study 34057124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 36113170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal cell treatments (NurOwn®)
Number of subjects: 18
Study 32198929 — intervention group
Group type: EXPERIMENTAL
Intervention: NICOM
Number of subjects: 75
Study 32198929 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic
Number of subjects: 75
Study 32198929 — intervention group
Group type: COMPARATOR
Intervention: Empirical
Number of subjects: 75
Study 33826038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Cognitive Behavioral Therapy (CBT)
Number of subjects: 167
Study 33826038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Cognitive Behavioral Therapy (CBT)
Number of subjects: 167
Study 33826038 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 167
Study 33896589 — intervention group
Group type: COMPARATOR
Intervention: Esketamine and placebo
Number of subjects: 20
Study 33896589 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine and sodium nitroprusside
Number of subjects: 20
Study 33896589 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine and placebo
Number of subjects: 20
Study 33896589 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine and sodium nitroprusside
Number of subjects: 20
Study 33896589 — intervention group
Group type: EXPERIMENTAL
Intervention: S-norketamine
Number of subjects: 20
Study 36314686 — intervention group
Group type: EXPERIMENTAL
Intervention: Target systolic blood pressure <120 mm Hg
Number of subjects: 0
Study 36314686 — intervention group
Group type: COMPARATOR
Intervention: Target systolic blood pressure <140/90 mm Hg
Number of subjects: 0
Study 36314686 — intervention group
Group type: COMPARATOR
Intervention: Target systolic blood pressure <130/80 mm Hg
Number of subjects: 0
Study 35131013 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic graded rewarming measures
Number of subjects: 104
Study 35131013 — intervention group
Group type: COMPARATOR
Intervention: Traditional rewarming measures
Number of subjects: 104
Study 36421345 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Number of subjects: 40
Study 36421345 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial (chemo-) embolization (TAE/TACE)
Number of subjects: 40
Study 34511121 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme (2-month duration)
Number of subjects: 196
Study 34511121 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 196
Study 32507446 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosomal curcumin (250 mg/day) for 8 weeks
Number of subjects: 54
Study 32507446 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 54
Study 35037118 — intervention group
Group type: COMPARATOR
Intervention: Non-washing group (Group 1)
Number of subjects: 168
Study 35037118 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with water alone group (Group 2)
Number of subjects: 168
Study 35037118 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with water and soap group (Group 3)
Number of subjects: 168
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia
Number of subjects: 146
Study 33712224 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia and Opioid-based anaesthesia
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: High D'Amico risk
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 tumour pathology
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: N1 status
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive surgical margins
Number of subjects: 146
Study 33712224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia technique
Number of subjects: 146
Study 32424878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT-I)
Number of subjects: 136
Study 32424878 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 136
Study 34534510 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine management using mobile phone
Number of subjects: 97
Study 34534510 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine intervention
Number of subjects: 97
Study 33145753 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP+TH
Number of subjects: 5330
Study 33145753 — intervention group
Group type: COMPARATOR
Intervention: LEEP
Number of subjects: 5330
Study 36130300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance
Number of subjects: 1280
Study 36130300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1280
Study 33004749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus capecitabine (NX)
Number of subjects: 97
Study 33004749 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus capecitabine (TX)
Number of subjects: 97
Study 34952708 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 806
Study 34952708 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 806
Study 33723117 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 40
Study 33723117 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 40
Study 32536118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position extubation
Number of subjects: 60
Study 32536118 — intervention group
Group type: COMPARATOR
Intervention: Supine position extubation
Number of subjects: 60
Study 33594185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 128
Study 33594185 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 128
Study 32808383 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multi-component physical activity module (including a Fitbit tracker and customized email feedback)
Number of subjects: 50
Study 35343269 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM+FBI
Number of subjects: 0
Study 35343269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-CGM
Number of subjects: 0
Study 35343269 — intervention group
Group type: COMPARATOR
Intervention: BGM-Crossover
Number of subjects: 0
Study 33537703 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator nerve block (ONB)
Number of subjects: 60
Study 33537703 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular block (NMB)
Number of subjects: 60
Study 32398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise (SE)
Number of subjects: 77
Study 32398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Exercise (WE)
Number of subjects: 77
Study 34980598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus sapanisertib 4 mg daily
Number of subjects: 141
Study 34980598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus sapanisertib 30 mg weekly
Number of subjects: 141
Study 34980598 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg (control)
Number of subjects: 141
Study 32387326 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and landscape image in postoperative hospital rooms
Number of subjects: 133
Study 32387326 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital room without music or landscape
Number of subjects: 133
Study 32127847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron weight adjusted dosing at 0.1mg/kg
Number of subjects: 124
Study 32127847 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 4mg ondansetron
Number of subjects: 124
Study 35093978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculus Go
Number of subjects: 9
Study 35093978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculus Quest
Number of subjects: 9
Study 35093978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenovo Mirage Solo
Number of subjects: 9
Study 35093978 — intervention group
Group type: COMPARATOR
Intervention: Comparison between headsets
Number of subjects: 9
Study 35093978 — intervention group
Group type: EXPERIMENTAL
Intervention: All headsets
Number of subjects: 9
Study 34477818 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1) administered at various doses: 70 mg, 350 mg, 500 mg every 2 weeks; 500 mg every 3 weeks; and 10 mg/kg every 2 weeks.
Number of subjects: 31
Study 34477818 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1) administered at various doses.
Number of subjects: 31
Study 32289353 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of contamination framework
Number of subjects: 100
Study 32289353 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist in the intervention arm
Number of subjects: 100
Study 35640729 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEi)
Number of subjects: 1999
Study 35640729 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1999
Study 32586079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 30 minutes, 5 times weekly for 48 weeks
Number of subjects: 52
Study 32586079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 60 minutes, 5 times weekly for 48 weeks
Number of subjects: 52
Study 32586079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 52
Study 35924272 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 400
Study 35924272 — intervention group
Group type: COMPARATOR
Intervention: Routine public health crisis intervention measures
Number of subjects: 400
Study 32312152 — intervention group
Group type: EXPERIMENTAL
Intervention: Male cyberbully/male cybervictim
Number of subjects: 176
Study 32312152 — intervention group
Group type: EXPERIMENTAL
Intervention: Male cyberbully/female cybervictim
Number of subjects: 176
Study 32312152 — intervention group
Group type: EXPERIMENTAL
Intervention: Female cyberbully/male cybervictim
Number of subjects: 176
Study 32312152 — intervention group
Group type: EXPERIMENTAL
Intervention: Female cyberbully/female cybervictim
Number of subjects: 176
Study 32046755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic augmentation of the wound with absorbable mesh
Number of subjects: 0
Study 32046755 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable mesh
Number of subjects: 0
Study 32046755 — intervention group
Group type: COMPARATOR
Intervention: Biologic/biosynthetic meshes
Number of subjects: 0